Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine triple antiemetic regimen and gene polymorphisms in chemotherapy-induced nausea and vomiting
ChiCTR2400084269Phase 3Completed
- Sponsor
- Ordos Central Hospital
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced nausea and vomiting (CINV) comparing Olanzapine triple antiemetic regimen with Placebo plus standard antiemetic regimen (2 arms). Primary endpoint: Complete protection rate during total, acute, and delayed periods after chemotherapy. Started May 2024; status: completed.
02
Drugs
olanzapine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR2400084269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084269.